United Therapeutics Corp

Day range

$584.50 – $592.56

Open

$589.11

Prev close

$587.50

Volume

303.7K

Market cap

$25.2B

Shares out

42.89M

P/E

19.22

P/S

7.99

P/B

3.94

P/FCF

23.05

ROE

20.5%

ROA

18.2%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Share repurchase programOct 22, 2026

  On October 21, 2026, the Board of Directors of United Therapeutics Corporation (the Company) approved a share repurchase program (the Share Repurchase Program), authorizing the purchase by the Company of up to $2.0 billion of the Company's common stock. This authorization will remain in effect for a one-year period ending October 21, 2027.

• Settlement agreementOct 14, 2026

  On October 13, 2026, United Therapeutics Corporation (UT) entered into a Settlement Agreement with Liquidia Technologies, Inc. that provides for the resolution of pending litigation between the parties. Under the Settlement Agreement, the parties have agreed to seek dismissal with prejudice of all of the foregoing actions within ten days after UT receives the $185 million payment described below.

• Share repurchase programSep 8, 2026

  “On September 8, 2026, United Therapeutics Corporation (the Company) entered into an accelerated share repurchase agreement (the ASR Agreement) with Citibank, N.A. (Citi) to repurchase approximately $477.6 million in the aggregate of the Company's common stock (Common Stock) under the Company's previously announced share repurchase program.”

• Director appointmentJul 23, 2026

  On July 22, 2026, the Board of Directors (the Board) of United Therapeutics Corporation (the Company), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Victor Dzau, M.D., to serve as a member of the Board.

• Equity compensation grantJun 29, 2026

  The 2026 Plan allows grants of stock options, stock appreciation rights, restricted stock, restricted stock units, and stock awards, any of which may be performance-based, and for incentive bonuses. Pursuant to the 2026 Plan, the aggregate number of shares of our common stock that may be issued under the 2026 Plan equal (A) the sum of (i) the shares that remain available for grant under the Prior Plan as of the effective date of the 2026 Plan plus (ii) 1,500,000 new shares.

Days to cover

3.6

Short interest

3.6M

Avg volume

995.62K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
  negativeZacks Investment Research· Oct 14, 2026
• SGIOY or UTHR: Which Is the Better Value Stock Right Now?
  positiveZacks Investment Research· Oct 14, 2026
• Why Investors Need to Take Advantage of These 2 Medical Stocks Now
  positiveZacks Investment Research· Oct 14, 2026
• Why Investors Need to Take Advantage of These 2 Medical Stocks Now
  positiveZacks Investment Research· Oct 9, 2026
• LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Oct 7, 2026